Abeona Therapeutics
ABEO
65 hedge funds and large institutions have $170M invested in Abeona Therapeutics in 2024 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 4 closing their positions.
22,275% more call options, than puts
Call options by funds: $3.58M | Put options by funds: $16K
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
18% more funds holding
Funds holding: 55 → 65 (+10)
4.06% more ownership
Funds ownership: 66.38% → 70.44% (+4.1%)
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
6% less capital invested
Capital invested by funds: $182M → $170M (-$11.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.01M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.14M |
| 3 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$2.38M |
| 4 |
Goldman Sachs
New York
|
+$825K |
| 5 |
Jane Street
New York
|
+$728K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$1.69M |
| 2 |
Millennium Management
New York
|
-$1.14M |
| 3 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$632K |
| 4 |
JP Morgan Chase
New York
|
-$413K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$308K |
ABEO Hedge Fund Activity: Q4 2024 in Review
65 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q4 2024, worth a combined $170M — down 6.2% from $182M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ABEO positions and 4 closed out — a net gain of 10 holders — while 16 added to existing stakes and 15 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $4.01M. The largest seller was Walleye Capital, cutting an estimated $1.69M.
- 65 institutional investors held Abeona Therapeutics (ABEO) as of Q4 2024, up from 55 in Q3 2024.
- Funds reported $170M of Abeona Therapeutics stock for Q4 2024, down 6.2% quarter-over-quarter.
- 14 funds opened new Abeona Therapeutics positions in Q4 2024 and 4 closed out, a net change of +10 holders.
- The largest Abeona Therapeutics buyer in Q4 2024 was Adage Capital Partners, an estimated $4.01M added.
- The largest Abeona Therapeutics seller in Q4 2024 was Walleye Capital, an estimated $1.69M sold.
Based on aggregated 13F filings for Q4 2024.